grant
A Phase 1 Adaptive Dose Escalation Study of Mycophenolate Mofetil in Combination with Temozolomide for Patients with Newly Diagnosed Glioblastoma
Organization NORTHWESTERN UNIVERSITYLocation CHICAGO, UNITED STATESPosted 17 Aug 2018Deadline 31 Jul 2028
NIHUS FederalResearch GrantFY20255'-Inosinic acidADP-Ribosylation FactorsARF Protein CofactorAbscissionAccountabilityAdjuvantAfter CareAfter-TreatmentAftercareAmino AcidsAnabolismBiogenesisBiological MarkersBloodBlood Reticuloendothelial SystemBody TissuesBrain CancerBrain NeoplasiaBrain NeoplasmsBrain TumorsCNS Nervous SystemCRISPR editing screenCRISPR screenCRISPR-based screenCRISPR/Cas9 screenCancersCell BodyCell divisionCellsCentral Nervous SystemCharacteristicsChemoresistanceCiliaClinicalCombined Modality TherapyDNADNA DamageDNA InjuryDataDehydrogenasesDeoxyribonucleic AcidDiagnosisDoseDrugsENX-1EZH1EZH2EZH2 geneEarly-Stage Clinical TrialsEffectivenessEligibilityEligibility DeterminationEnhancer of Zeste 2 Polycomb Repressive Complex 2 SubunitEnrollmentEnzyme GeneEnzymesEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessEvaluationExcisionExtirpationFDA approvedGenesGlioblastomaGoalsGrade IV Astrocytic NeoplasmGrade IV Astrocytic TumorGrade IV AstrocytomaGrafting ProcedureHPLCHigh Performance Liquid ChromatographyHigh Pressure Liquid ChromatographyHigh Speed Liquid ChromatographyIRBIRBsIn VitroInosine MonophosphateInstitutional Review BoardsKMT6KMT6ALaboratoriesMALD-MSMALDIMALDI-MSMaintenanceMalignant CellMalignant NeoplasmsMalignant TumorMalignant Tumor of the BrainMalignant neoplasm of brainMaximal Tolerated DoseMaximally Tolerated DoseMaximum Tolerated DoseMediatingMedicationMetabolicMethodsMolecularMonitorMultimodal TherapyMultimodal TreatmentMycophenolic AcidNeuraxisNewly DiagnosedNon-Polyadenylated RNANormal CellNucleotide SynthesisOperative ProceduresOperative Surgical ProceduresOrgan TransplantationOrgan TransplantsOrigin of LifeOxidoreductaseOxidoreductase GenePDX modelPathway interactionsPatient derived xenograftPatient outcomePatient-Centered OutcomesPatient-Focused OutcomesPatientsPeripheralPharmaceutical PreparationsPhasePhase 1 Clinical TrialsPhase 1/1b Clinical TrialPhase 1/1b trialPhase I Clinical TrialsPhase I/IB Clinical TrialPolycombPredispositionPrimary Brain NeoplasmsPrimary Brain TumorsPrognosisPropertyProtein FamilyProteinsProtocolProtocol ScreeningProtocols documentationPurine Metabolism PathwayPurinesPurines/Pyrimidines/Nucleotides/Nucleic Acids MetabolismR2 GeneRNARNA Gene ProductsRR2 GeneRRM2RRM2 geneRadiation therapyRadiotherapeuticsRadiotherapyRecommendationRecurrenceRecurrentRecurrent NeoplasmRecurrent tumorRecyclingReductasesRemovalRepressor ProteinsResistanceRibonucleic AcidRibonucleoside-Diphosphate Reductase M2 Chain GeneRibonucleotide ReductaseRibonucleotide Reductase M2 Polypeptide GeneRibonucleotide Reductase Small Chain GeneRibosylhypoxanthine MonophosphateSafetySlideSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationSpectroscopy, Mass, Matrix-Assisted Laser Desorption-IonizationStressSurgicalSurgical InterventionsSurgical ProcedureSurgical RemovalSusceptibilitySystemTemodalTemodarTherapeuticTherapeutic InterventionTissuesToxic effectToxicitiesTreatment EfficacyTumor TissueValidationWorkXenograft Modelaminoacidarmbio-markersbiologic markerbiomarkerbiomarker identificationbiosynthesiscancer cellcancer initiationcell typechemoresistantchemotherapychemotherapy resistancechemotherapy resistantclinical translationclinical trial protocolclinically translatableclustered regularly interspaced short palindromic repeats screencombination therapycombined modality treatmentcombined treatmentdrug/agenteffective therapyeffective treatmentenrollenzyme biosynthesisepigeneticallyfitnessgene networkgenome scalegenome-widegenomewideglioblastoma multiformeidentification of biomarkersidentification of new biomarkersimprovedin vivointervention efficacyintervention therapyknock-downknockdownmalignancymarker identificationmatrix assisted laser desorption ionizationmembermetabolism measurementmetabolomicsmetabonomicsmethazolastonemouse modelmulti-modal therapymulti-modal treatmentmurine modelmycophenolate mofetilmycophenolic acid morpholinoethyl esterneoplasm recurrenceneoplasm/cancernovelnucleotide metabolismorgan allograftorgan graftorgan xenograftoverexpressoverexpressionpathwaypatient derived xenograft modelpatient oriented outcomespatient populationpatient prognosisphase I protocolpost treatmentpredict clinical outcomepredictive biological markerpredictive biomarkerspredictive markerpredictive molecular biomarkerpreventpreventingprimary end pointprimary endpointpurine metabolismradiation treatmentrepressor complexresectionresistance to therapyresistantresistant to therapyresponse to therapyresponse to treatmentsecondary end pointsecondary endpointsmall moleculespatial RNA sequencingspatial gene expression analysisspatial gene expression profilingspatial resolved transcriptome sequencingspatial transcriptome analysisspatial transcriptome profilingspatial transcriptome sequencingspatial transcriptomicsspatially resolved transcriptomicsspatio transcriptomicsspongioblastoma multiformestandard carestandard of carestandard treatmentsurgerytemozolomidetherapeutic efficacytherapeutic resistancetherapeutic responsetherapeutically effectivetherapy efficacytherapy resistanttherapy responsetranslation strategytranslational approachtranslational strategytreatment resistancetreatment responsetreatment responsivenesstreatment with radiationtumortumors in the brainvalidationsxenograft transplant modelxenotransplant model
Description preview
PROJECT 4: PROJECT SUMMARY
Glioblastoma (GBM), a grade IV tumor, is one of the most aggressive and infiltrative brain cancer forms. Patients
currently diagnosed with Glioblastoma (GBM) have an abysmal prognosis. The median survival is around 8-10
months, even after the standard care protocol of surgical resection followed by alkylating…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click